Seeking Alpha

Nymox Pharmaceutical (NYMX +0.6%) ticks up after saying that Phase 3 immunogenicity trials of...

Nymox Pharmaceutical (NYMX +0.6%) ticks up after saying that Phase 3 immunogenicity trials of its lead drug candidate NX-1207 have not shown any evidence of eliciting an immune reaction in men treated with intraprostatic injections of the drug.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)